JP2020515610A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515610A5 JP2020515610A5 JP2019553572A JP2019553572A JP2020515610A5 JP 2020515610 A5 JP2020515610 A5 JP 2020515610A5 JP 2019553572 A JP2019553572 A JP 2019553572A JP 2019553572 A JP2019553572 A JP 2019553572A JP 2020515610 A5 JP2020515610 A5 JP 2020515610A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- compound according
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 111
- 150000001875 compounds Chemical class 0.000 claims description 106
- 125000003545 alkoxy group Chemical group 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 44
- 125000001475 halogen functional group Chemical group 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 208000002193 Pain Diseases 0.000 claims description 25
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 17
- 125000004104 aryloxy group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- -1 halo-C 1-6 alkylthio Chemical group 0.000 claims description 9
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 8
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 8
- 125000005138 alkoxysulfonyl group Chemical group 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 8
- 150000004074 biphenyls Chemical group 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 6
- 125000004802 cyanophenyl group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 206010015958 Eye pain Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- 206010011224 Cough Diseases 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000006561 Cluster Headache Diseases 0.000 claims description 2
- 206010061788 Corneal infection Diseases 0.000 claims description 2
- 208000028006 Corneal injury Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 208000027520 Somatoform disease Diseases 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 231100000321 erythema Toxicity 0.000 claims description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000003497 sciatic nerve Anatomy 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 208000020049 trigeminal nerve disease Diseases 0.000 claims description 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 0 CC(*1)(CN(C2)C(NC[C@@](C=*3)NC3=[N+])=NC)[C@@]2N1C(C)=O Chemical compound CC(*1)(CN(C2)C(NC[C@@](C=*3)NC3=[N+])=NC)[C@@]2N1C(C)=O 0.000 description 12
- DIAAYZGONSGOTP-UHFFFAOYSA-N Cc1cccc2c1OCCC21CC1 Chemical compound Cc1cccc2c1OCCC21CC1 DIAAYZGONSGOTP-UHFFFAOYSA-N 0.000 description 2
- 108010052164 Sodium Channels Proteins 0.000 description 2
- 102000018674 Sodium Channels Human genes 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical class NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 2
- XJWNRCKYCHREJD-UHFFFAOYSA-N CC(C)c1c2OCCC3(CCC3)c2ccc1 Chemical compound CC(C)c1c2OCCC3(CCC3)c2ccc1 XJWNRCKYCHREJD-UHFFFAOYSA-N 0.000 description 1
- ZAVDOSIMBQUKCN-UHFFFAOYSA-N CCc1cccc2c1OCC21CC1 Chemical compound CCc1cccc2c1OCC21CC1 ZAVDOSIMBQUKCN-UHFFFAOYSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762478523P | 2017-03-29 | 2017-03-29 | |
| US62/478,523 | 2017-03-29 | ||
| PCT/US2018/025301 WO2018183781A1 (en) | 2017-03-29 | 2018-03-29 | 11,13-modified saxitoxins for the treatment of pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515610A JP2020515610A (ja) | 2020-05-28 |
| JP2020515610A5 true JP2020515610A5 (enExample) | 2021-05-20 |
| JP7090100B2 JP7090100B2 (ja) | 2022-06-23 |
Family
ID=62063184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553572A Active JP7090100B2 (ja) | 2017-03-29 | 2018-03-29 | 疼痛の処置のための１１，１３－修飾サキシトキシン： |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11236097B2 (enExample) |
| EP (1) | EP3601291A1 (enExample) |
| JP (1) | JP7090100B2 (enExample) |
| KR (1) | KR20200012833A (enExample) |
| CN (1) | CN110831945B (enExample) |
| AU (1) | AU2018243463C1 (enExample) |
| BR (1) | BR112019020111A2 (enExample) |
| CA (1) | CA3058214A1 (enExample) |
| IL (1) | IL269599B2 (enExample) |
| MX (1) | MX2019011530A (enExample) |
| WO (1) | WO2018183781A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110831945B (zh) | 2017-03-29 | 2023-08-08 | 赛特温治疗公司 | 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 |
| JP2020515611A (ja) * | 2017-03-29 | 2020-05-28 | サイトワン セラピューティクス， インコーポレイテッド | 疼痛の処置のための１１，１３−修飾サキシトキシン |
| EP3860714B1 (en) | 2018-10-03 | 2023-09-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| CN110128292A (zh) * | 2019-06-12 | 2019-08-16 | 成都美域高制药有限公司 | 一种Ozanimod中间体4-氰基茚酮的合成方法 |
| LT4069691T (lt) | 2019-12-06 | 2024-12-10 | Vertex Pharmaceuticals Incorporated | Pakeistieji tetrahidrofuranai kaip natrio kanalų moduliatoriai |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| CN117794919A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂 |
| CN117858875A (zh) | 2021-06-04 | 2024-04-09 | 沃泰克斯药物股份有限公司 | 羟基和(卤代)烷氧基取代的四氢呋喃作为钠通道调节剂 |
| EP4346818B1 (en) | 2021-06-04 | 2025-12-03 | Vertex Pharmaceuticals Incorporated | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
| EP4347032A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| WO2023205778A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CR20240513A (es) | 2022-04-22 | 2025-04-30 | Vertex Pharma | Compuestos de heteroarilo para el tratamiento del dolor |
| WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CN119487003A (zh) | 2022-04-22 | 2025-02-18 | 沃泰克斯药物股份有限公司 | 用于治疗疼痛的杂芳基化合物 |
| CN120603815A (zh) | 2022-12-06 | 2025-09-05 | 沃泰克斯药物股份有限公司 | 钠通道的取代四氢呋喃调节剂的合成方法 |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| TW202523313A (zh) | 2023-10-23 | 2025-06-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
| TW202535867A (zh) | 2023-10-23 | 2025-09-16 | 美商維泰克斯製藥公司 | 用於治療疼痛之鈉通道調節劑及其固體形式的製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3957996A (en) | 1971-12-08 | 1976-05-18 | Astra Pharmaceutical Products, Inc. | Pharmaceutical local anesthetic compositions |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| EP0857972A1 (en) | 1997-01-24 | 1998-08-12 | Tepual, S.A. | Immunoassay for the detection and quantitation of toxins causing paralytic shellfish poisoning |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| CN1081034C (zh) | 1997-03-07 | 2002-03-20 | 潘心富 | 一种双胍基氢化嘌呤环类化合物的戒毒药 |
| WO1998043619A2 (en) | 1997-04-02 | 1998-10-08 | The Regents Of The University Of California | Method of local anesthesia |
| US6326020B1 (en) | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CN1382443A (zh) | 2001-04-25 | 2002-12-04 | 威克斯医疗仪器有限公司 | 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用 |
| JP2003012699A (ja) | 2001-07-04 | 2003-01-15 | Japan Science & Technology Corp | 抗麻酔性貝毒抗体の製法、新規抗体、該抗体を用いるｅｌｉｓａ測定キット、該製法による系標識毒標品 |
| CN1194693C (zh) | 2002-01-11 | 2005-03-30 | 中国科学院海洋研究所 | 麻痹性贝毒毒素作为制备疗治疼痛病症药物的应用 |
| WO2004050034A2 (en) | 2002-12-02 | 2004-06-17 | Massachusetts Institute Of Technology | Prolonged suppression of electrical activity in excitable tissues |
| AU2003901897A0 (en) | 2003-02-12 | 2003-05-08 | Australian Institute Of Marine Science | Conjugate |
| US20050137177A1 (en) | 2003-12-18 | 2005-06-23 | Shafer Steven L. | Ester combination local anesthetic |
| JP5047782B2 (ja) | 2004-05-07 | 2012-10-10 | ファイトトックス リミテッド | フィコトキシン及びその使用 |
| AU2005244096B2 (en) | 2004-05-07 | 2011-03-17 | Algenis Spa | Transdermal administration of phycotoxins |
| WO2006032459A1 (en) | 2004-09-22 | 2006-03-30 | Laboratorios Del Dr. Esteve S.A. | Tetrodotoxin and its derivatives for the treatment of peripheral-nervously derived neuropathic pain |
| RU2277097C1 (ru) | 2004-12-27 | 2006-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Высокомеченный тритием дигидрохлорид [3h]сакситоксина |
| AU2006243644A1 (en) | 2005-05-05 | 2006-11-09 | Phytotox Limited | Use of phycotoxins in veterinary applications |
| CN101513408A (zh) | 2008-02-19 | 2009-08-26 | 熊平 | 双胍基嘌呤环类衍生物制备提高抗癌药药效的新应用 |
| WO2010027641A2 (en) | 2008-08-15 | 2010-03-11 | Georgetown University | Na channels, disease, and related assays and compositions |
| US9174999B2 (en) | 2009-05-07 | 2015-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for studying, imaging, and treating pain |
| WO2011098539A1 (en) | 2010-02-10 | 2011-08-18 | Phytotox Limited | Treatment of loss of sense of touch with saxitoxin derivatives |
| US20140187533A1 (en) | 2011-03-03 | 2014-07-03 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| HUE046795T2 (hu) | 2011-11-15 | 2020-03-30 | St Pharm Co Ltd | Új vírusellenes pirrolopiridin származékok és eljárás azok elõállítására |
| AU2015243437B2 (en) * | 2014-04-09 | 2019-08-29 | Siteone Therapeutics, Inc. | 10',11'-modified saxitoxins useful for the treatment of pain |
| CN108473503A (zh) * | 2015-09-30 | 2018-08-31 | 赛特温治疗公司 | 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 |
| JP2020515611A (ja) | 2017-03-29 | 2020-05-28 | サイトワン セラピューティクス， インコーポレイテッド | 疼痛の処置のための１１，１３−修飾サキシトキシン |
| CN110831945B (zh) | 2017-03-29 | 2023-08-08 | 赛特温治疗公司 | 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物 |
| EP3860714B1 (en) | 2018-10-03 | 2023-09-06 | Siteone Therapeutics, Inc. | 11,13-modified saxitoxins for the treatment of pain |
| BR112023002659A2 (pt) | 2020-08-14 | 2023-05-02 | Siteone Therapeutics Inc | Inibidores de cetona não hidratados de nav1.7 para o tratamento da dor |
-
2018
- 2018-03-29 CN CN201880035534.4A patent/CN110831945B/zh active Active
- 2018-03-29 US US16/499,205 patent/US11236097B2/en active Active
- 2018-03-29 EP EP18720448.2A patent/EP3601291A1/en active Pending
- 2018-03-29 AU AU2018243463A patent/AU2018243463C1/en active Active
- 2018-03-29 CA CA3058214A patent/CA3058214A1/en active Pending
- 2018-03-29 KR KR1020197031530A patent/KR20200012833A/ko not_active Ceased
- 2018-03-29 BR BR112019020111A patent/BR112019020111A2/pt not_active Application Discontinuation
- 2018-03-29 MX MX2019011530A patent/MX2019011530A/es unknown
- 2018-03-29 WO PCT/US2018/025301 patent/WO2018183781A1/en not_active Ceased
- 2018-03-29 JP JP2019553572A patent/JP7090100B2/ja active Active
-
2019
- 2019-09-24 IL IL269599A patent/IL269599B2/en unknown
-
2022
- 2022-01-26 US US17/585,530 patent/US11834456B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515610A5 (enExample) | ||
| EP2870150B1 (en) | Heterocyclic modulators of lipid synthesis | |
| JP6893501B2 (ja) | スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン | |
| JP2020515611A5 (enExample) | ||
| JP7554410B2 (ja) | Ｓｔｉｎｇ（インターフェロン遺伝子刺激因子）のモジュレーター | |
| JP2018534270A5 (enExample) | ||
| US11052091B2 (en) | BRK inhibitory compound | |
| KR101671761B1 (ko) | 이미다조옥사진 화합물에 의한 항종양 효과 증강제 | |
| TW201808888A (zh) | 整合應激途徑之調節劑 | |
| WO1997037989A1 (en) | Indole derivatives as 5-ht receptor antagonist | |
| HK1250159A1 (zh) | Brk抑制性化合物 | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| CN112218851A (zh) | 整合应激通路的调节剂 | |
| EP4034534A1 (en) | Polyheterocyclic modulators of sting (stimulator of interferon genes) | |
| JP2011509309A5 (enExample) | ||
| KR970705393A (ko) | 암 치료를 위한 화합물 및 방법(compounds and methods for the treatment of cancer) | |
| JP2007505933A5 (enExample) | ||
| JP2006524662A5 (enExample) | ||
| CN102985421A (zh) | 作为pi3k抑制剂用于治疗癌症和免疫-炎性疾病的萘啶衍生物 | |
| KR20130083389A (ko) | 야누스 키나아제 억제제로서 헤테로사이클릭 화합물 | |
| TWI827576B (zh) | 吲哚胺2,3-雙加氧酶抑制劑以及它們在醫學上的應用 | |
| JP2007516292A5 (enExample) | ||
| JP2005531563A5 (enExample) | ||
| KR20240113429A (ko) | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도 | |
| CN110049768A (zh) | 酚噻嗪衍生物及其使用方法 |